The market of medicines, also called life science market or biotech market, is one of the largest and fastest growing markets. An ageing population, today’s possibility of developing precision medicine, as well as evolving cell- and gene-therapy, are just some of the drivers for this growth. On top of that, people in emerging markets also want to have access to Western medicine which fuel sales figures in these territories to a double digit growth.
The two most important reasons to invest in Aescap 2.0 is first of all our outstanding track record in comparison with Exchange Traded Funds (ETFs) and relevant indexes realized by a very experience and hands-on team. Secondly, it is to enable the development of better medical treatments.
Our outperformance is based on an effective strategy. Given the correlation between share prices of biotech companies is only 20%, it makes it one of the best markets for stock picking. We pick and choose around 18 high growth companies to invest in, based on a fundamental analysis of innovative medicine companies. Over time, this portfolio of companies changes based on a constant assessment of the portfolio and the fact that we take our profit ones a portfolio company is not any longer undervalued.
Based on a disciplined buy and sell strategy we make use of the typical gloom and doom stories that often appear in our industry. It also prevents us from going along with a bubble. We have a regular dialogue with the management of the companies we invest in to see if they are still on the ball and if their vision of the future of the company is still realistic.
Entry into the fund can take place twice a month in parallel with the determination of the net asset value. An investment in the fund can be initiated by sending the subscription form to SGG Financial Services B.V, via firstname.lastname@example.org. SGG Financial Services B.V is responsible for the fund- and participant administration. In parallel the subscription amount needs to be transferred to the bank account of the Legal Owner: ‘Stichting Aescap 2.0’, bank account IBAN: NL51ABNA0494667826, under the subject ‘Investment in Aescap 2.0’. The minimum subscription amount is €500.000,-. You will receive a confirmation of your investment from SGG Financial Services B.V. after the completion of their client due diligence and upon receipt of the subscription form and investment amount Investors will also receive a unique username and password to have excess to your personal investor information on the website of the fund administrator SGG at all times.
Additional investments need to take place through the same bank account as you have used with the fund before when the initial investment was made. You need to transfer the additional Investment Amount to Stichting Aescap 2.0, IBAN: NL51ABNA0494667826 and state under ‘subject’: ‘Investment in Aescap 2.0’. Your additional investment can be made twice a month.